Brentuximab Vedotin
Brentuximab Vedotin
Immunoglobulin G1-κ auristatin E conjugate, anti-[Homo sapiens TNFRSF8 (tumor necrosis factor receptor superfamiliy member 8, KI-1, CD30)], chimeric monoclonal antibody conjugated to auristatin E; γ1 heavy chain (1-446) [Mus musculus VH (IGHV1-84*02 -(IGHD)-IGHJ3*01) [8.8.10] (1-117) -Homo sapiens IGHG1*01 CH3K130>del (118-446)], (220-218′)-disulfide (if not conjugated) with κ light chain (1′-218′) [Mus musculus V-KAPPA (IGKV3-4*01 -IGKJ1*01) [10.3.9] (1′-111′) -Homo sapiens IGKC*01 (112′-218′)]; (226-226′′)-disulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to monomethylauristatin E (MMAE), via amaleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-valcit-PABC) linker
Stoffgruppe
Antineoplastisches Mittel, Antikörper-Wirkstoff-Konjugat
Halbwertszeit
4-6 Tage
Präparate
ADCETRIS 50 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Brentuximab Vedotin